Description: Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Home Page: www.kezarlifesciences.com
4000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
650 822 5600
Officers
| Name | Title |
|---|---|
| Mr. John Franklin Fowler | Co-Founder, CEO & Director |
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Pres, Chief Scientific Officer & Director |
| Dr. Noreen Roth Henig M.D. | Chief Medical Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Mr. Marc L. Belsky | CFO & Sec. |
| Mr. Michael Wolfe | Sr. VP of Fin. & Bus. Operations |
| Ms. Gitanjali Jain | VP of Investor Relations & External Affairs |
| Mr. Mark Schiller | Sr. VP of Legal Affairs |
| Dr. Neel K. Anand Ph.D. | VP of Medicinal Chemistry & Head of Drug Discovery |
| Dr. Nick Mordwinkin Ph.D., Pharm.D. | Chief Bus. Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6696 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |